News coverage about OHR Pharmaceutical (NASDAQ:OHRP) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. OHR Pharmaceutical earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 46.2548553843099 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
A number of research firms recently issued reports on OHRP. Zacks Investment Research upgraded OHR Pharmaceutical from a “hold” rating to a “buy” rating and set a $0.75 price objective on the stock in a research report on Wednesday, October 25th. ValuEngine lowered OHR Pharmaceutical from a “sell” rating to a “strong sell” rating in a research report on Friday, January 5th. Finally, Roth Capital cut OHR Pharmaceutical from a “buy” rating to a “neutral” rating and set a $7.00 target price for the company. in a report on Friday, January 5th.
Shares of OHR Pharmaceutical (OHRP) opened at $0.32 on Thursday. OHR Pharmaceutical has a fifty-two week low of $0.31 and a fifty-two week high of $2.18. The firm has a market capitalization of $17.88, a P/E ratio of -0.54 and a beta of 0.48.
OHR Pharmaceutical (NASDAQ:OHRP) last released its quarterly earnings data on Friday, December 15th. The biotechnology company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08).
WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect OHR Pharmaceutical (OHRP) Stock Price” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/01/ohr-pharmaceuticals-ohrp-given-daily-media-sentiment-score-of-0-12.html.
OHR Pharmaceutical Company Profile
OHR Pharmaceutical, Inc, a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.
Receive News & Ratings for OHR Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OHR Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.